regulatory
confidence high
sentiment negative
materiality 0.75
Zomedica Corp. (ZOMDF): Nasdaq/NYSE listing notice — Zomedica continues NYSE American listing dialogue after shareholder rejection of reverse split
Zomedica Corp.
- Received NYSE American deficiency letter Sept 2023 for 30-day avg share price below $0.20 per Section 1003(f)(v).
- Shareholders rejected proposed 80:1 reverse stock split at Feb 28, 2024 special meeting; 67.7% majority required.
- Shares remain listed; exchange will monitor price and further deterioration could trigger delisting.
- CEO Larry Heaton cites progress and opportunities to positively impact share price.